Journal Pre-Print Describes How CytoDyn’s Leronlimab Disrupts CCL5/RANTES-CCR5 Pathway, Thereby Restoring Immune Homeostasis, Reducing Plasma Viral Load, & Reversing Hyper-Immune Activation and Inflammation in Critical COVID-19 Patients

On May 5,2020, CytoDyn Inc. (OTC.QB: CYDY), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5-antagonist with the potential for multiple therapeutic indications, announced that a pre-print version of the manuscript has been made publicly available on posting on the Research Square and MedRxiv portals. The pre-print will soon be finalized and published in a prestigious journal. The pre-prom describes the immunological mechanism by which CytoDyn’s HIV drug leronlimab restores immune function and impacts disease in COVID-19 patients. Consistent with CytoDyn’s commitment to disseminate results to inform the public health response to SARS-CoV-2, the manuscript has been made publicly available as a pre-print prior to final journal publication, which should occur shortly. The manuscript is entitled: “Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19.” The pre-print full manuscript can be accessed at: ( and ( The manuscript has been submitted for publication and is currently under peer review. The pre-print manuscript has also been shared with the World Health Organization (WHO). As described in the pre-print, in a cohort of ten critically ill patients, after treatment with leronlimab, these critically ill patients experienced reversed hyper immune activation and inflammation, as well as reversed immunosuppression, thereby facilitating a more effective immune response correlated with decreases in SARS-CoV-2 virus levels in blood.
Login Or Register To Read Full Story